byiShook Opinion
Apr 22, 2025 - 19:35
Shares of Bristol Myers Squibb tumbled late Tuesday after the company's schizophrenia drug, Cobenfy, failed in a Phase 3 study. The post Bristol Myers Sheds 6% After Promising Schizophrenia Drug Flops In Phase 3 Test appeared first on Investor's Business Daily.
Shares of Bristol Myers Squibb tumbled late Tuesday after the company's schizophrenia drug, Cobenfy, failed in a Phase 3 study.
The post Bristol Myers Sheds 6% After Promising Schizophrenia Drug Flops In Phase 3 Test appeared first on Investor's Business Daily.